American judo coach suffers vision loss in JetBlue coffee air incident
Article content
Arturas Lanchinskas, 30, a third-degree black belt, was flying to Peru to coach the American team at the Pan American Judo Championships in July 2023 when the incident happened.
Article content
Article content
Lanchinskas owns Darfight Martial Arts in Brooklyn and was on JetBule Flight 1825 when a flight attendant allegedly dropped a pot of scalding coffee, according to the Daily Mail.
Article content
The coffee burned his face and right eye, according to a lawsuit obtained by Dailymail.com.
Article content
'As a result of the hot coffee splashing onto Plaintiff's face and into his eye, he was caused to sustain severe burns to the right side of his face and severe injuries to his right eye,' the lawsuit reads.
Article content
'It felt like a surge of fire hit the surface of my eyeball,' Lanchinskas told The New York Post. 'The pain was sharp and immediate, like a burning needle.'
Article content
Coincidentally, the passenger seated next to Lanchinskas was a doctor and told him to flush his eye repeatedly with water.
Article content
But the lawsuit alleges flight attendants were mad at Lanchinskas for using the washroom too often to flush his eye with water.
Article content
Attorney, Erin R. Applebaum said in the lawsuit that the flight attendants were complaining that other passengers needed to use the bathroom.
Article content
'He was even told, 'Sir, you're not the only one on the airplane, we have other guests who need to use the facilities,'' Applebaum said.
Article content
Once the plane landed, Lanchinskas was rushed to a local hospital in Lima, where doctors treated the burns to his face and eye. But he was later diagnosed with a thermal injury and chemical burn to his right eye.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
CAR T-Cell Therapy for Multiple Myeloma Pipeline Experiences Rapid Expansion as Over 5+ Leading Companies Advance Novel Therapies
DelveInsight's, 'CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2025,' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the CAR T-Cell Therapy for Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy for Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Dive into DelveInsight's comprehensive report today! @ CAR T-Cell Therapy for Multiple Myeloma Pipeline Outlook Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report In July 2025, Janssen Research & Development LLC announced a study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). DelveInsight's CAR T-Cell Therapy for Multiple Myeloma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CAR T-Cell Therapy for Multiple Myeloma treatment. The leading CAR T-Cell Therapy for Multiple Myeloma Companies such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. Promising CART-Cell Therapy for Multiple Myeloma Pipeline Therapies such as Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. Stay ahead with the most recent pipeline outlook for CAR T-Cell Therapy for Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ CAR T-Cell Therapy for Multiple Myeloma Treatment Drugs CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Profile Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the multiple myeloma treatment. JNJ-68284528: Janssen Biotech Janssen's drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status. The CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment. CAR T-Cell Therapy for Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market Explore groundbreaking therapies and clinical trials in the CAR T-Cell Therapy for Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New CAR T-Cell Therapy for Multiple Myeloma Drugs CAR T-Cell Therapy for Multiple Myeloma Companies Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Product Type Unveil the future of CAR T-Cell Therapy for Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers Scope of the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report Coverage- Global CAR T-Cell Therapy for Multiple Myeloma Companies- Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation and others. CART-Cell Therapy for Multiple Myeloma Pipeline Therapies- Cevostamab, Talquetamab, Bortezomib, Dexamethasone, Lenalidomide, Nivolumab and others. CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on CAR T-Cell Therapy for Multiple Myeloma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ CAR T-Cell Therapy for Multiple Myeloma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary CAR T-Cell Therapy for Multiple Myeloma: Overview Pipeline Therapeutics Therapeutic Assessment CAR T-Cell Therapy for Multiple Myeloma – DelveInsight's Analytical Perspective In-depth Commercial Assessment CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals Early Stage Products (Phase I) PHE 885: Novartis Drug profiles in the detailed report….. Pre-clinical Stage JNJ-68284528: Janssen Biotech Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products CAR T-Cell Therapy for Multiple Myeloma Key Companies CAR T-Cell Therapy for Multiple Myeloma Key Products CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion CAR T-Cell Therapy for Multiple Myeloma Analyst Views CAR T-Cell Therapy for Multiple Myeloma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Insight 2025: 75+ Companies Accelerating Innovation Across Genetic and Neuroinflammatory Targets
The ALS pipeline is gaining momentum, with over 75 companies advancing R&D across key targets like SOD1 mutations, TDP-43, C9orf72 expansions, and neuroinflammation. Approaches include ASOs, gene therapies, mitochondrial modulators, neuroprotective agents, and immune biologics. A major milestone was the FDA's 2023 accelerated approval of Biogen and Ionis's Tofersen for SOD1-ALS. DelveInsight's ' Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025 ' offers a detailed analysis of the evolving therapeutic landscape for ALS, a fatal neurodegenerative disease characterized by progressive loss of motor neurons, leading to muscle weakness, paralysis, and eventually respiratory failure. With most patients succumbing to the disease within 3–5 years of symptom onset, there remains a critical unmet need for effective disease-modifying treatments. Several late-stage candidates are progressing through global Phase II/III studies, including Amylyx's AMX0035, which received full FDA approval in September 2022 as RELYVRIO, and is now being evaluated in confirmatory trials. Additionally, investigational programs from companies like Clene Nanomedicine, QurAlis, Wave Life Sciences, and BrainStorm Cell Therapeutics are advancing promising assets in both sporadic and familial ALS subpopulations, often with orphan drug or fast-track designations. The regulatory landscape continues to support innovation in ALS with flexible pathways and growing biomarker guidance, including neurofilament light chain (NfL) levels, digital endpoints, and functional scores. Patient advocacy, real-world evidence generation, and adaptive trial designs are also helping de-risk development strategies and accelerate access. As 2025 unfolds, the ALS pipeline reflects a shift from symptomatic care to precision medicine and disease modification, driven by robust collaboration among academia, biotech, regulatory bodies, and patient communities. With over 80 therapies in the pipeline, the future of ALS treatment is poised for transformative change. Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report • DelveInsight's amyotrophic lateral sclerosis pipeline analysis depicts a strong space with 75+ active players working to develop 80+ pipeline drugs for amyotrophic lateral sclerosis treatment. • The leading amyotrophic lateral sclerosis companies include Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating their lead assets to improve the amyotrophic lateral sclerosis treatment landscape. • Key amyotrophic lateral sclerosis pipeline therapies in various stages of development include ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others. • In July 2025, Neurizon Therapeutics submitted a formal response to the FDA addressing the clinical hold on its IND application for NUZ-001, its lead ALS therapy. • In July 2025, Klotho Neurosciences received FDA Orphan Drug Designation for KLTO-202 ( its novel gene therapy targeting ALS. • In June 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that the FDA granted Fast Track designation to AMX0114, an investigational antisense oligonucleotide targeting calpain-2 for treating ALS. • In May 2025, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced FDA clearance to begin its Phase IIIb trial of NurOwn® for treating amyotrophic lateral sclerosis (ALS). • In May 2025, Neuralink announced that it received the FDA's " breakthrough" designation for its device aimed at restoring communication for individuals with severe speech impairment. The device, designed to assist patients with conditions like ALS, stroke, spinal cord injury, cerebral palsy, and multiple sclerosis, represents a significant step forward in neurotechnology. • In March 2025, DiagnaMed Holdings Corp. announced a significant milestone in rare disease research, receiving Orphan Drug Designation (ODD) from the FDA for molecular hydrogen in the treatment of ALS. • In January 2025, the FDA granted approval for Zydus Lifesciences to proceed with a randomized Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for the treatment of ALS. Request a sample and discover the recent breakthroughs happening in the amyotrophic lateral sclerosis pipeline landscape. Amyotrophic Lateral Sclerosis Overview Amyotrophic Lateral Sclerosis (ALS) is a rare, progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. It leads to the loss of muscle control, eventually impacting the ability to speak, move, eat, and breathe. ALS is often classified into sporadic (the most common form) and familial types, with the latter being linked to genetic mutations. Although the exact cause of ALS is unknown in most cases, environmental and genetic factors are believed to contribute to its development. Currently, there is no cure for ALS, but several treatment options aim to slow disease progression and manage symptoms. FDA-approved drugs like riluzole and edaravone offer modest benefits in extending survival or preserving function. Ongoing research is focused on gene therapies, neuroprotective agents, and immune-targeting approaches to better address the underlying mechanisms of the disease and improve patient outcomes. Find out more about amyotrophic lateral sclerosis medication at Amyotrophic Lateral Sclerosis Treatment Analysis: Drug Profile MN-166: MediciNova MN-166 is an orally administered small molecule glial attenuator that reduces neuroinflammation by suppressing pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6, while potentially increasing the anti-inflammatory cytokine IL-10. It also functions as a toll-like receptor 4 (TLR4) antagonist, contributing further to its anti-inflammatory effects. MN-166 is currently in Phase II/III clinical trials for the treatment of ALS. RNS60: Revalesio RNS60 is designed to offer disease-modifying and potentially regenerative effects in neurological disorders. It works by activating signaling pathways that enhance mitochondrial function and reduce inflammation, offering neuroprotection and immune modulation. The FDA has granted RNS60 both Orphan Drug and Fast Track status for ALS. It is currently in Phase II clinical trials. VM202: Helixmith VM202 is a gene therapy aimed at tissue regeneration by promoting the production of hepatocyte growth factor (HGF) at the site of injection along peripheral nerves. HGF supports nerve protection, neuron growth, and muscle atrophy prevention. The FDA has granted VM202 Orphan Drug and Fast Track designations. It is being evaluated in Phase II trials for ALS treatment. Learn more about the novel and emerging amyotrophic lateral sclerosis pipeline therapies. By Product Type • Mono • Combination • Mono/Combination. By Stage • Late-stage products (Phase III) • Mid-stage products (Phase II) • Early-stage product (Phase I) along with the details of • Pre-clinical and Discovery stage candidates • Discontinued & Inactive candidates By Route of Administration • Intravenous • Subcutaneous • Oral • Intramuscular By Molecule Type • Monoclonal antibody • Small molecule • Peptide Scope of the Amyotrophic Lateral Sclerosis Pipeline Report • Coverage: Global • Key Amyotrophic Lateral Sclerosis Companies: Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others. • Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others. Explore detailed insights on drugs used in the treatment of amyotrophic lateral sclerosis here. Table of Contents 1. Introduction 2. Executive Summary 3. Amyotrophic Lateral Sclerosis Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics 6. Amyotrophic Lateral Sclerosis Pipeline: Late-Stage Products (Phase III) 7. Amyotrophic Lateral Sclerosis Pipeline: Mid-Stage Products (Phase II) 8. Amyotrophic Lateral Sclerosis Pipeline: Early Stage Products (Phase I) 9. Therapeutic Assessment 10. Inactive Products 11. Company-University Collaborations (Licensing/Partnering) Analysis 12. Key Companies 13. Key Products 14. Unmet Needs 15. Market Drivers and Barriers 16. Future Perspectives and Conclusion 17. Analyst Views 18. Appendix About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
National Post
5 hours ago
- National Post
There is a serious side effect to going to space, NASA says
A new study from NASA, conducted over several years of long-duration spaceflights on the International Space Station, has found that more than half of U.S. astronauts started noticing changes in their vision after more than six months aboard the ISS. Here's what to know. Article content What does the study say? Article content Article content 'Many found that, as their mission progressed, they needed stronger reading glasses,' the study says. 'Researchers studying this phenomenon identified swelling in the optic disc, which is where the optic nerve enters the retina, and flattening of the eye shape.' Article content Article content What is causing it? Article content A Canadian-led study with an even longer acronym — Space Flight-Associated Neuro-ocular Syndrome Ocular Rigidity Investigation, or SANSORI — was carried out to determine whether stiffness of the eye, called ocular rigidity, contributes to development of SANS. Article content It studied 26 eyes (or 13 crew members) that spent between 157 and 186 days on the ISS, and revealed a drop in ocular rigidity (33 per cent), intraocular pressure (11 per cent) and ocular pulse amplitude (25 per cent) following the missions. 'These findings reveal previously unknown effects of microgravity on the eye's mechanical properties, contributing to a deeper understanding of … SANS,' researchers wrote. 'Long-term space missions significantly alter ocular biomechanics and have the potential to become biomarkers of disease progression.' Article content Article content What kinds of treatment have been tried? Article content Article content NASA has a study taking place now on the space station with a device called the Thigh Cuff. The ongoing investigation has 10 astronauts using tight leg cuffs to change the way fluid moves around inside the body, especially around the eyes and in the heart and blood vessels. Article content That study is expected to wrap up next year but, if successful, the team behind the device says, 'the cuffs could serve as a countermeasure against the problems associated with fluid shifts, including SANS.' Article content They add: 'A simple and easy-to-use tool to counter the headward shift of body fluids could help protect astronauts on future missions to the Moon and Mars. The cuffs also could treat conditions on Earth that cause fluid to build up in the head or upper body, such as long-term bed rest and certain diseases.' Article content Other possible treatments have been considered. Last year, a paper was published about an unnamed female astronaut with a particularly severe case of SANS. Her condition improved after she started taking a prescribed B-vitamin supplement that was flown to her on the station; however, there was coincidentally a reduction in cabin carbon dioxide at the same time, so researchers weren't certain if that may have also helped.
